Pub Date : 2026-02-01DOI: 10.1016/S2352-3026(26)00003-7
Emma Wilkinson
{"title":"Jorge Cortes: building a network of leukaemia expertise in Latin America.","authors":"Emma Wilkinson","doi":"10.1016/S2352-3026(26)00003-7","DOIUrl":"https://doi.org/10.1016/S2352-3026(26)00003-7","url":null,"abstract":"","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":"13 2","pages":"e61"},"PeriodicalIF":17.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-02-02DOI: 10.1016/S2352-3026(25)00321-7
Prasanna Ananth, Jerlym S Porter, Jacklyn Boggs, Griffin Collins, Francesca A Williamson, Nitya Bakshi, Jane S Hankins, Liza-Marie Johnson, Ronit Elk, Dylan E Graetz, Erica C Kaye
Haematological disorders constitute a public health crisis in more than 160 countries worldwide. Despite millions afflicted, people with haematological diagnoses remain underserved and understudied. This Review, one of four companion Reviews on qualitative research published in The Lancet Oncology, The Lancet Haematology, and eClinicalMedicine, reports findings from a symposium of international multidisciplinary experts in applied qualitative research, highlighting the purpose and added value of qualitative research for improving health outcomes for people with haematological disorders and their communities. First, we describe how applied qualitative research elevates the voices of marginalised populations, review gaps in the current science, and present examples of impactful qualitative research in haematology across the research lifecycle. Second, we spotlight the need for global uptake of applied qualitative methods for people with haematological disorders to address questions related to health equity, care access, treatment adherence, and ethical implications of participation in therapeutic trials. Finally, we present an expert-informed roadmap for the conduct and appraisal of qualitative research in haematology comprising five pillars (engagement, flexibility, transparency, transferability, and impact) to promote best practices for applied qualitative research in haematology.
{"title":"Expert recommendations for the conduct and appraisal of qualitative research in haematology.","authors":"Prasanna Ananth, Jerlym S Porter, Jacklyn Boggs, Griffin Collins, Francesca A Williamson, Nitya Bakshi, Jane S Hankins, Liza-Marie Johnson, Ronit Elk, Dylan E Graetz, Erica C Kaye","doi":"10.1016/S2352-3026(25)00321-7","DOIUrl":"10.1016/S2352-3026(25)00321-7","url":null,"abstract":"<p><p>Haematological disorders constitute a public health crisis in more than 160 countries worldwide. Despite millions afflicted, people with haematological diagnoses remain underserved and understudied. This Review, one of four companion Reviews on qualitative research published in The Lancet Oncology, The Lancet Haematology, and eClinicalMedicine, reports findings from a symposium of international multidisciplinary experts in applied qualitative research, highlighting the purpose and added value of qualitative research for improving health outcomes for people with haematological disorders and their communities. First, we describe how applied qualitative research elevates the voices of marginalised populations, review gaps in the current science, and present examples of impactful qualitative research in haematology across the research lifecycle. Second, we spotlight the need for global uptake of applied qualitative methods for people with haematological disorders to address questions related to health equity, care access, treatment adherence, and ethical implications of participation in therapeutic trials. Finally, we present an expert-informed roadmap for the conduct and appraisal of qualitative research in haematology comprising five pillars (engagement, flexibility, transparency, transferability, and impact) to promote best practices for applied qualitative research in haematology.</p>","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":" ","pages":"e110-e118"},"PeriodicalIF":17.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146127204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/S2352-3026(26)00001-3
Gerard Gurumurthy, Laura Knox, Jecko Thachil, Imelda Bates, Stephen P Hibbs
{"title":"Questions from the woman in the painting: revisiting chlorosis.","authors":"Gerard Gurumurthy, Laura Knox, Jecko Thachil, Imelda Bates, Stephen P Hibbs","doi":"10.1016/S2352-3026(26)00001-3","DOIUrl":"https://doi.org/10.1016/S2352-3026(26)00001-3","url":null,"abstract":"","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":"13 2","pages":"e62-e63"},"PeriodicalIF":17.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/S2352-3026(25)00315-1
Tayyiba Wasim, Natasha Bushra, Tahira Nasrin, Shamsa Humayun, Arif Tajammul, Khadija Irfan Khawaja, Sonia Irshad, Sara Fatima, Adeela Yasin, Javier Zamora, Naomi Cano-Ibáñez, Borja Manuel Fernandez-Felix, Khalid Saeed Khan
<p><strong>Background: </strong>In non-anaemic iron deficiency during pregnancy, it remains unclear whether the administration of intravenous iron improves maternal and infant outcomes, compared with prophylactic oral iron that is currently recommended for antenatal care. This study evaluated whether the addition of intravenous iron to routine oral prophylaxis had an effect on maternal haemoglobin concentration before delivery in non-anaemic iron deficient pregnant women.</p><p><strong>Methods: </strong>In this multicentre, two-arm, randomised trial done at three teaching hospitals in Lahore, Pakistan, pregnant women aged 18 years or older with a singleton pregnancy were screened at the first antenatal care booking visit for non-anaemic iron deficiency (haemoglobin 11-13 g/dL at booking with ferritin <30 μg/L). Women with high haemoglobin concentrations were excluded. Participants were randomly assigned (1:1) to an intervention during the second trimester using serially numbered, opaque, identical boxes, prepared by a third party using computer-generated random numbers with variable block sizes. Participants were assigned to either receive 1000 mg of intravenous iron in addition to routine oral iron prophylaxis, or to receive prophylactic 30 mg oral iron daily as the standard of routine care throughout pregnancy. Outcome assessors were masked to group allocation. Participants were followed up to delivery. The primary outcome was the mean change in maternal haemoglobin concentration from baseline to 36 weeks' gestation. We performed the primary analysis applying the intention-to-treat principle in all randomly assigned participants who had data for the primary outcome available (full analysis set). We assessed participants for serious or life-threatening adverse events such as death, cardiac arrest, myocardial infarction, anaphylactic shock, and reactions leading to intensive care admission and discontinuation of treatment. The trial is registered at ClinicalTrials.gov number, NCT04228627, and is completed.</p><p><strong>Findings: </strong>Between Jan 14, 2020, to Aug 29, 2023, 1206 women were screened for eligibility, 606 were ineligible for participation due to reasons including age, gestational age, and haemoglobin concentration, and 600 were enrolled in the study. 295 women were assigned to the intravenous iron group and 305 were assigned to the oral iron prophylaxis group, and all were followed up until delivery. 228 women delivered in the intravenous iron group (14 preterm), and 234 women delivered in the oral iron prophylaxis group (21 preterm; three without primary outcome data). Maternal haemoglobin concentration before delivery was 11·6 g/dL (SD 0·5) in the intravenous iron group and 10·8 g/dL (0·7) in the prophylactic oral iron group (mean difference, 0·74 g/dL [95% CI 0·64-0·85]; p<0·0001). None of the participants experienced serious or life-threatening adverse events.</p><p><strong>Interpretation: </strong>Among non-anaemic iron defi
{"title":"Intravenous iron for non-anaemic iron deficiency in pregnancy: a multicentre, two-arm, randomised controlled trial.","authors":"Tayyiba Wasim, Natasha Bushra, Tahira Nasrin, Shamsa Humayun, Arif Tajammul, Khadija Irfan Khawaja, Sonia Irshad, Sara Fatima, Adeela Yasin, Javier Zamora, Naomi Cano-Ibáñez, Borja Manuel Fernandez-Felix, Khalid Saeed Khan","doi":"10.1016/S2352-3026(25)00315-1","DOIUrl":"10.1016/S2352-3026(25)00315-1","url":null,"abstract":"<p><strong>Background: </strong>In non-anaemic iron deficiency during pregnancy, it remains unclear whether the administration of intravenous iron improves maternal and infant outcomes, compared with prophylactic oral iron that is currently recommended for antenatal care. This study evaluated whether the addition of intravenous iron to routine oral prophylaxis had an effect on maternal haemoglobin concentration before delivery in non-anaemic iron deficient pregnant women.</p><p><strong>Methods: </strong>In this multicentre, two-arm, randomised trial done at three teaching hospitals in Lahore, Pakistan, pregnant women aged 18 years or older with a singleton pregnancy were screened at the first antenatal care booking visit for non-anaemic iron deficiency (haemoglobin 11-13 g/dL at booking with ferritin <30 μg/L). Women with high haemoglobin concentrations were excluded. Participants were randomly assigned (1:1) to an intervention during the second trimester using serially numbered, opaque, identical boxes, prepared by a third party using computer-generated random numbers with variable block sizes. Participants were assigned to either receive 1000 mg of intravenous iron in addition to routine oral iron prophylaxis, or to receive prophylactic 30 mg oral iron daily as the standard of routine care throughout pregnancy. Outcome assessors were masked to group allocation. Participants were followed up to delivery. The primary outcome was the mean change in maternal haemoglobin concentration from baseline to 36 weeks' gestation. We performed the primary analysis applying the intention-to-treat principle in all randomly assigned participants who had data for the primary outcome available (full analysis set). We assessed participants for serious or life-threatening adverse events such as death, cardiac arrest, myocardial infarction, anaphylactic shock, and reactions leading to intensive care admission and discontinuation of treatment. The trial is registered at ClinicalTrials.gov number, NCT04228627, and is completed.</p><p><strong>Findings: </strong>Between Jan 14, 2020, to Aug 29, 2023, 1206 women were screened for eligibility, 606 were ineligible for participation due to reasons including age, gestational age, and haemoglobin concentration, and 600 were enrolled in the study. 295 women were assigned to the intravenous iron group and 305 were assigned to the oral iron prophylaxis group, and all were followed up until delivery. 228 women delivered in the intravenous iron group (14 preterm), and 234 women delivered in the oral iron prophylaxis group (21 preterm; three without primary outcome data). Maternal haemoglobin concentration before delivery was 11·6 g/dL (SD 0·5) in the intravenous iron group and 10·8 g/dL (0·7) in the prophylactic oral iron group (mean difference, 0·74 g/dL [95% CI 0·64-0·85]; p<0·0001). None of the participants experienced serious or life-threatening adverse events.</p><p><strong>Interpretation: </strong>Among non-anaemic iron defi","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":"13 1","pages":"e22-e29"},"PeriodicalIF":17.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145893275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/S2352-3026(25)00320-5
Khaled M Musallam, Sujit Sheth, Maria Domenica Cappellini, Farrukh Shah, Stefano Rivella, Vijay G Sankaran, Kevin H M Kuo, Vip Viprakasit, Androulla Eleftheriou, Michael Angastiniotis, Franco Locatelli, Ali T Taher
β-thalassaemia is an inherited haemoglobinopathy characterised by ineffective erythropoiesis and chronic anaemia of varying severity, which is predominant in the region extending from the Mediterranean basin and Middle East towards southeast Asia. Patients with severe phenotypes require lifelong transfusions, iron overload monitoring, and chelation. Suboptimal management due to access challenges continues to be directly linked to increased morbidity and mortality in many regions. In the past few decades, an improved understanding of the underlying pathogenesis of β-thalassaemia has led to the development of several disease-modifying therapies and curative gene manipulation techniques. However, global disparities in access and the need for specialised expertise hinder their wide implementation, especially in resource-limited countries where more than 80% of patients live. Uncertainty about which biomarkers can predict patient response further complicates the selection of patients for treatment. Beyond the need for access programmes and pragmatic national health policies, patient prioritisation by treating physicians, informed by available evidence and expert opinion, is crucial for ensuring that a resource-cautious management approach is implemented. This Viewpoint provides a decision matrix to prioritise interventions by need, benefit, and risk in settings with inadequate access, and to identify alternatives when standard options are unavailable. It draws on the Thalassaemia International Federation guidelines, best available trial and real-world evidence, and expert consensus from virtual discussions among the authors (haematologists, bone marrow transplantation physicians, patient group representatives, translational scientists, and trialists).
{"title":"Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources.","authors":"Khaled M Musallam, Sujit Sheth, Maria Domenica Cappellini, Farrukh Shah, Stefano Rivella, Vijay G Sankaran, Kevin H M Kuo, Vip Viprakasit, Androulla Eleftheriou, Michael Angastiniotis, Franco Locatelli, Ali T Taher","doi":"10.1016/S2352-3026(25)00320-5","DOIUrl":"https://doi.org/10.1016/S2352-3026(25)00320-5","url":null,"abstract":"<p><p>β-thalassaemia is an inherited haemoglobinopathy characterised by ineffective erythropoiesis and chronic anaemia of varying severity, which is predominant in the region extending from the Mediterranean basin and Middle East towards southeast Asia. Patients with severe phenotypes require lifelong transfusions, iron overload monitoring, and chelation. Suboptimal management due to access challenges continues to be directly linked to increased morbidity and mortality in many regions. In the past few decades, an improved understanding of the underlying pathogenesis of β-thalassaemia has led to the development of several disease-modifying therapies and curative gene manipulation techniques. However, global disparities in access and the need for specialised expertise hinder their wide implementation, especially in resource-limited countries where more than 80% of patients live. Uncertainty about which biomarkers can predict patient response further complicates the selection of patients for treatment. Beyond the need for access programmes and pragmatic national health policies, patient prioritisation by treating physicians, informed by available evidence and expert opinion, is crucial for ensuring that a resource-cautious management approach is implemented. This Viewpoint provides a decision matrix to prioritise interventions by need, benefit, and risk in settings with inadequate access, and to identify alternatives when standard options are unavailable. It draws on the Thalassaemia International Federation guidelines, best available trial and real-world evidence, and expert consensus from virtual discussions among the authors (haematologists, bone marrow transplantation physicians, patient group representatives, translational scientists, and trialists).</p>","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":"13 1","pages":"e49-e54"},"PeriodicalIF":17.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145893377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/S2352-3026(25)00344-8
The Lancet Haematology
{"title":"Lymphoma in the BiTE era.","authors":"The Lancet Haematology","doi":"10.1016/S2352-3026(25)00344-8","DOIUrl":"https://doi.org/10.1016/S2352-3026(25)00344-8","url":null,"abstract":"","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":"13 1","pages":"e1"},"PeriodicalIF":17.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145893404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/S2352-3026(25)00343-6
Roanna D M Maharaj
{"title":"Living between roles: navigating professional and patient identities with thalassaemia.","authors":"Roanna D M Maharaj","doi":"10.1016/S2352-3026(25)00343-6","DOIUrl":"https://doi.org/10.1016/S2352-3026(25)00343-6","url":null,"abstract":"","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":"13 1","pages":"e4-e5"},"PeriodicalIF":17.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145893406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/S2352-3026(25)00297-2
Farouk Kabbara, Nicole Charbel, Joseph Klim, Sacha El Khoury, Hassan Fawaz, Suzanne Koussa, Rayan Bou-Fakhredin, Ali Taher
{"title":"Thalassaemia clinical trials in war-stricken Lebanon: a story of struggle and resilience.","authors":"Farouk Kabbara, Nicole Charbel, Joseph Klim, Sacha El Khoury, Hassan Fawaz, Suzanne Koussa, Rayan Bou-Fakhredin, Ali Taher","doi":"10.1016/S2352-3026(25)00297-2","DOIUrl":"10.1016/S2352-3026(25)00297-2","url":null,"abstract":"","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":"13 1","pages":"e6-e7"},"PeriodicalIF":17.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145893429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号